BRCA

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

Retrieved on: 
Wednesday, March 27, 2024
Toxicity, Ovarian cancer, BRCA, Mirvetuximab soravtansine, Partnership, Patient, Neoplasm, Cancer, Merck, Doctor of Philosophy, Olaparib, WNT, Niraparib, Jiangsu Hengrui Medicine, PARP, Therapy, Safety, Platinum, Interim, Rucaparib, Pharmaceutical industry

This decisive shift in priorities is driven by the compelling initial data from the Phase 2 monotherapy trial evaluating stenoparib in advanced, recurrent ovarian cancer patients, as announced on December 5, 2023.

Key Points: 
  • This decisive shift in priorities is driven by the compelling initial data from the Phase 2 monotherapy trial evaluating stenoparib in advanced, recurrent ovarian cancer patients, as announced on December 5, 2023.
  • In addition, stenoparib is unique in its mechanism of action, inhibiting PARP as well as the novel cancer target, tankyrase.
  • Tankyrase inhibition would restrain the WNT pathway, which is commonly upregulated not only in ovarian cancers but in many other solid cancers.
  • Given the unique, dual mechanism of action for stenoparib—coupled with its favorable safety profile—stenoparib may represent the next-generation alternative in the evolving market for advanced ovarian cancer patients.

GTG Global Collaborations and Innovation Update

Retrieved on: 
Tuesday, March 26, 2024
Breast cancer, Health, General practice, Professor, BRCA, Public, Public health, Disease, GTG, Risk, Patient, PRS, Research, ASX, Breast, Mammography, University, Royal Melbourne Hospital, Trial of the century, WHI, Risk assessment, Sonneborn–Berger score, Council, Biobank, Publication, Clinical trial, Cancer, CLIA, Medical research, Colorectal cancer, University of Melbourne, Government, UK Biobank, Pharmaceutical industry

MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation.

Key Points: 
  • MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation.
  • GTG is one of the co-co-principal investigators of this trial led by Professor Jon Emery.
  • GTG regards adding new expanded risk assessment tests to the company’s portfolio as a critical step in improving patient care.
  • Leveraging this approach GTG is expanding the portfolio with the following new tests:
    Leveraging the BRCA-modifier research projects GTG will develop a test that incorporates high penetrant pathogenic variant risk with PRS.

Accent Therapeutics Presents Data Supporting Two Lead Programs at AACR 2024 Annual Meeting

Retrieved on: 
Monday, April 8, 2024
BRCA, DNA repair, Mitosis, Apoptosis, Breast, PD, RME, Patient, DHX9, Neoplasm, Data, RNA, DNA, Cancer, Accent, Enzyme, AACR, Therapy, Breast cancer, BRCA2, Pharmaceutical industry

LEXINGTON, Mass., April 8, 2024 /PRNewswire/ -- Accent Therapeutics, a biopharmaceutical company pioneering a novel class of small molecule precision cancer therapeutics presents advances in cancer targeting, including data on DHX9 and KIF18A inhibitor activity in multiple tumor types, at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.

Key Points: 
  • "Accent has expanded the potential of our two lead programs in preclinical investigations, and we are excited for the promise they hold for addressing cancers with high unmet clinical need," said Robert A. Copeland, Ph.D., President, Founder, and Chief Scientific Officer of Accent Therapeutics.
  • "Our results reveal that DHX9 and KIF18A inhibition are potent therapeutic strategies that stand to benefit large patient populations.
  • These findings validate our systematic approach to tapping the rich therapeutic potential of our target space."
  • These data are highlighted in a presentation entitled "DHX9 inhibition as a novel therapeutic for cancer with loss-of-function mutations in DNA damage repair genes BRCA1 and BRCA2."

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Friday, April 5, 2024
Technology, Research, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Clinical trial, PDT, Macrophage, Downregulation and upregulation, Ovarian cancer, BRCA, ECM, Pericyte, Apoptosis, Nanoparticle, Cervical cancer, GBM, Patient, Neoplasm, Doxorubicin, Traffic barrier, Cancer, Triple-negative breast cancer, Proteomics, AACR, Glioblastoma, Pancreatic cancer, Phenotype, PARP, Cisplatin, Immunogenic cell death, Large intestine, TNBC, Animal, PDGFR, Pharmaceutical industry

Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego.
  • Presentations from Novocure-sponsored and partner programs include:
    Tumor Treating Fields (TTFields) targeted self assembling nanoparticles for pancreatic cancer treatment: In vitro and in vivo assessment.
  • Tumor Treating Fields (TTFields) induce an anti-tumor immune response in a pancreatic cancer mouse model.
  • Tumor Treating Fields (TTFields) show efficacy in Triple-Negative breast cancer (TNBC) cells alone and in combination with PARP inhibitor Talazoparib.

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

Retrieved on: 
Tuesday, April 2, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, Breast cancer, Goserelin, Patient, Lung, Social media, Immunoglobulin G, National Cancer Institute, Neoplasm, Merck & Co., TNBC, Capecitabine, DXD, BRCA, Clinical Cancer Research, Metabolism, Immunology, Biopharmaceutical, World Health Organization, Cancer, Safety, ADC, BLA, Daiichi Sankyo, Vinorelbine, IHC, Mutation, NSCLC, Disease, Merck, AKT, Death, MD, AstraZeneca, PARP, Oncotarget, PFS, FDA, OS, HER2, Eribulin, Cleavage, Progression-free survival, Triple-negative breast cancer, Female, Emerging, Olaparib, Biology, Sapporo Medical University, Medicine, Pharmaceutical industry

The safety profile of datopotamab deruxtecan was consistent with that observed in other ongoing trials with no new safety concerns identified.

Key Points: 
  • The safety profile of datopotamab deruxtecan was consistent with that observed in other ongoing trials with no new safety concerns identified.
  • Additional regulatory submissions for datopotamab deruxtecan in lung and breast cancer are underway globally.
  • A comprehensive global clinical development program is underway with more than 20 trials evaluating the efficacy and safety of datopotamab deruxtecan across multiple cancers, including NSCLC, triple-negative breast cancer (TNBC) and HR-positive, HER2-negative breast cancer.
  • Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer.

Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ODD, Cancer, Research, PRMT5, Brain, Mutation, BRCA, NSCLC, NYU Langone Health, Breast, General counsel, Patient, GBM, Orphan, Collaboration, DNA, DevOps, MTAP, Sarcoma, Head, MTA, AACR, Glioblastoma, Clinical trial, PARP, Therapy, Drug development, ATM, ACS, Safety, Pharmacokinetics, Carcinoma, Corporate governance, FDA, American Chemical Society, Food, Pharmaceutical industry

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.

Key Points: 
  • Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.
  • “In 2023, we made meaningful progress developing precision oncology treatments and now have four ongoing phase 1/2 clinical trials.
  • The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to TNG462 in December 2023 for the treatment of soft tissue sarcomas.
  • The increase is the result of out-licensing a program to Gilead for $5.0 million during the second quarter of 2023.

SOPHiA GENETICS Announces First Homologous Recombination Deficiency (HRD) Customer in Canada

Retrieved on: 
Wednesday, March 20, 2024
Ovarian cancer, Gene, Mutation, BRCA, Genetic testing, Patient, NGS, Research, DNA, Guideline, AI, University, Cancer, Hope, Quality of life, GENETICS, Oncology, Medicine, Clinical trial, Sophia Genetics, HRD, HRR, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, March 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced the University of Saskatchewan (USask) as its first HRD customer in Canada. USask will implement the SOPHiA DDM™ Platform for use in its cutting-edge clinical trial, which aims to substantially improve the quality of life for ovarian cancer patients through expanded genetic testing. This is the first clinical trial in Canada designed to improve ovarian cancer treatment decisions and inspire guideline changes to increase access to advanced testing.

Key Points: 
  • BOSTON and ROLLE, Switzerland, March 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced the University of Saskatchewan (USask) as its first HRD customer in Canada.
  • This is the first clinical trial in Canada designed to improve ovarian cancer treatment decisions and inspire guideline changes to increase access to advanced testing.
  • It's exactly what we at SOPHiA GENETICS are working so hard to make available to clinician researchers around the world," said John Carey, Managing Director, NORAM, SOPHiA GENETICS.
  • The SOPHiA DDM™ Comprehensive Profiling Solution coupled with SOPHiA GENETICS' proprietary deep learning algorithm, GIInger™, will provide USask with a widespread look at potential mutations for each patient.

Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer

Retrieved on: 
Saturday, March 16, 2024
Diagnosis, Ovarian cancer, MIRV, Mutation, Health, BRCA, Science, Disease, Partnership, Patient, Education, Glomus tumor, Roche, Biomarker, Neoplasm, Research, Cancer, EOC, Recombinant DNA, Woman, HRP, PARP, TTD, Fibroadenoma, HRD, Mirvetuximab soravtansine, BRCA2, Recurrence, LH, BRCA1, ADP, Pharmaceutical industry

BURLINGTON, N.C., March 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today presented the results from two studies at the 2024 SGO Annual Meeting on Women's Cancer. The studies demonstrate the value of biomarker testing in closing testing gaps and guiding targeted therapies for patients with epithelial ovarian cancer (EOC).

Key Points: 
  • The studies demonstrate the value of biomarker testing in closing testing gaps and guiding targeted therapies for patients with epithelial ovarian cancer (EOC).
  • Labcorp researchers conducted two studies to generate further evidence of the value of comprehensive genomic profiling to drive guideline-compliant testing that enables increased patient access to targeted therapies for improved outcomes.
  • When combined, the results of BRCA and HRD testing can determine which patients are most likely to benefit from treatment with poly-ADP ribose polymerase (PARP) inhibitors.
  • "This research emphasizes the power of comprehensive biomarker testing in advancing the treatment of ovarian cancer.

Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Other Health, Health, General Health, Women, Pharmaceutical, Oncology, Research, Consumer, Science, Clinical Trials, Progression-free survival, Fudan University, Shanghai Cancer Center, ISD, PARP, ESGO, BRCA, HKEX, Platelet, OS, Gynecologic Oncology (journal), Ovarian cancer, SGO, Patient, Congress, Development, Niraparib, Pharmaceutical industry

“Previous progression-free survival and interim OS data from the NORA study demonstrated the benefit of niraparib maintenance therapy with an individualized starting dose among Chinese patients with PSROC,” said Dr. Rafael Amado, President, Head of Global Oncology Research and Development, Zai Lab.

Key Points: 
  • “Previous progression-free survival and interim OS data from the NORA study demonstrated the benefit of niraparib maintenance therapy with an individualized starting dose among Chinese patients with PSROC,” said Dr. Rafael Amado, President, Head of Global Oncology Research and Development, Zai Lab.
  • “We look forward to sharing the final OS findings from this study at both the 2024 ESGO and SGO conferences.
  • The final OS analysis was conducted after ≥ 50% of OS events occurred in the intent-to-treat population.
  • No new safety signals were identified during the long-term follow up period subsequent to the primary analysis.

Genetic Health Service Provider, Panacea, Launches to Make Whole Exome Sequencing Accessible to Consumers Without Insurance Barriers

Retrieved on: 
Wednesday, February 28, 2024
PALM, Breast cancer, Dahlia, Sequence, BRCA, Risk, Health, Ovarian cancer, CLIA, Ashkenazi Jews, Exome sequencing, Disease, Science, Mutation, CAP, Insurance, Cancer, Vaccine

PALM BEACH, Fla., Feb. 28, 2024 /PRNewswire/ -- Panacea, the one-stop-shop for genetic health services making potentially life-saving testing accessible for consumers, today announced its nationwide* commercial availability, without needing to visit a doctor or receive approval from insurance.

Key Points: 
  • The problem is that current guidelines for doctors to order genetic tests, and for insurance to approve it, are missing about half of the people with genetic mutations.
  • "I had my exome sequenced with Panacea, even though I was not a candidate for testing based on today's medical guidelines.
  • This further inspired me to make clinical-grade whole exome sequencing more accessible, so everyone can make informed decisions about their future."
  • For more information on Panacea or on whole exome sequencing, please visit seekpanacea.com .